Acumen and agility.
Experience and excitement.

Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients.

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

The Flare Team

managementall

Our Directors, Founders
and Advisors

boardfoundersadvisorsall
Abbie Celniker, Ph.D.
Abbie Celniker, Ph.D.
Board Chair
Aaron Davis
Aaron Davis
Board Member
Lorence Kim, M.D.
Lorence Kim, M.D.
Board Member
Jakob Loven, Ph.D.
Jakob Loven, Ph.D.
Board Member
Steven M. Paul, M.D.
Steven M. Paul, M.D.
Board Member
Fraydoon Rastinejad, Ph.D.
Fraydoon Rastinejad, Ph.D.
Founder
Steven L. McKnight, Ph.D.
Steven L. McKnight, Ph.D.
Founder
Mitchell Lazar, M.D., Ph.D.
Mitchell Lazar, M.D., Ph.D.
Founder
Robert Sims, Ph.D.
Robert Sims, Ph.D.
Founder
Stephen Frye, Ph.D.
Stephen Frye, Ph.D.
Advisor

INVESTORS

LIGHTING THE WAY

  Science

 

This links to an external website.

Continue